BEIJING, June 23, 2022 /PRNewswire/ Ocumension Therapeutics 1477.HKannounced that the New Drug Application (NDA) for the core product in its pipeline, OT-401 (Sterile non-bioerodible intravitreal implant, Product name: YUTIO), was officially approved by the National Pharmaceutical Administration (NMPA) for the treatment of chronic non-infectious uveitis involving the posterior segment of the eye (chronic NIU-PS). This is the first new drug in Ocumension's pipeline to be approved for marketing and is currently the potential best-in-class therapy for the treatment of this indication in China. Ocumension is a Chinese ophthalmic pharmaceutical platform company dedicated to identifying, developing and commercialising first-in-class or best-in-class ophthalmic therapies. To date, Ocumension has 23 drug assets in the immediate and posterior segments of the eye and has established a complete ophthalmic drug pipeline, of which seven products are in Phase III clinical trials and its core pr